Activities of the frog skin peptide, ascaphin-8 and its lysine-substituted analogs against clinical isolates of extended-spectrum β-lactamase (ESBL) producing bacteria

被引:22
作者
Eley, Adrian [2 ]
Ibrahim, Marwa [2 ]
El Kurdi, Sylvia [3 ]
Conlon, J. Michael [1 ]
机构
[1] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain 17666, U Arab Emirates
[2] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Med Microbiol, Al Ain 17666, U Arab Emirates
[3] Tawam Hosp, Clin Support Serv, Microbiol Serv, Al Ain 15258, U Arab Emirates
关键词
antibacterial peptide; ascaphin-8; extended-spectrum beta-lactamases; hemolysis;
D O I
10.1016/j.peptides.2007.10.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria are becoming increasingly prevalent and their antibiotic resistance necessitates novel therapeutic intervention. Ascaphin-8 is a cationic alpha-helical peptide that shows broad-spectrum antibacterial activity but is also toxic to human erythrocytes (LC50 = 55 mu M). This study assesses the activity of ascaphin-8, and a series Of L-lysine-substituted analogs, against a range of clinical isolates of ESBL-producing bacteria. All ESBL-producing Escherichia coli (MIC = 1.5-6 mu M) and Klebsiella pneumoniae (MIC = 12.5-25 mu M) strains tested were susceptible to ascaphin-8, as well as a group of miscellaneous ESBL-producing strains (Citrobacter, Salmonella, Serratia, Shigella spp.) (MIC <= 25 mu M). The Lys(4)- and Lys(8)-substituted analogs were generally the most potent against bacteria but showed the highest hemolytic activity. However, the Lys(10), Lys(14), and Lys(18) analogs also displayed potent antibacterial activity while showing very low hemolytic activity (LC50 > 500 mu M). An unexpected finding was the susceptibility of ESBL-producing Proteus mirabilis strains to ascaphin-8 (MIC = 12.5-25 mu M) and its Lys(4)-substituted analog (MIC = 6 mu M), although non-ESBL isolates of this organism were resistant to these peptides (MIC > 100 mu M). (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 24 条
[1]  
Clinical and Laboratory Standards Institute, 2006, M100S16 CLSINCCLS
[2]   Effect of aminoisobutyric acid (Aib) substitutions on the antimicrobial and cytolytic activities of the frog skin peptide, temporin-1DRa [J].
Conlon, J. Michael ;
Al-Kharrge, Rokaya ;
Ahmed, Eman ;
Raza, Haider ;
Galadari, Sehamuddin ;
Condamine, Eric .
PEPTIDES, 2007, 28 (10) :2075-2080
[3]   Strategies for transformation of naturally-occurring amphibian antimicrobial peptides into therapeutically valuable anti-infective agents [J].
Conlon, J. Michael ;
Al-Ghaferi, Nadia ;
Abraham, Bency ;
Leprince, Jerome .
METHODS, 2007, 42 (04) :349-357
[4]   Antimicrobial and cytolytic properties of the frog skin peptide, kassinatuerin-1 and its L- and D-lysine-substituted derivatives [J].
Conlon, JM ;
Abraham, B ;
Galadari, S ;
Knoop, FC ;
Sonnevend, A ;
Pál, T .
PEPTIDES, 2005, 26 (11) :2104-2110
[5]   The ascaphins:: a family of antimicrobial peptides from the skin secretions of the most primitive extant frog, Ascaphus truei [J].
Conlon, JM ;
Sonnevend, A ;
Davidson, C ;
Smith, DD ;
Nielsen, PF .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 320 (01) :170-175
[6]   The therapeutic potential of antimicrobial peptides from frog skin [J].
Conlon, JM .
REVIEWS IN MEDICAL MICROBIOLOGY, 2004, 15 (01) :17-25
[7]   Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides [J].
Dathe, M ;
Wieprecht, T ;
Nikolenko, H ;
Handel, L ;
Maloy, WL ;
MacDonald, DL ;
Beyermann, M ;
Bienert, M .
FEBS LETTERS, 1997, 403 (02) :208-212
[8]  
Giangaspero A, 2001, EUR J BIOCHEM, V268, P5589
[9]  
Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5
[10]   Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp. [J].
Leverstein-van Hall, MA ;
Fluit, AC ;
Paauw, A ;
Box, ATA ;
Brisse, S ;
Verhoef, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3703-3711